ArticleLeukemia2017
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03959371 (Observational, Retrospective and Prospective Study on the Use of Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy), which is not on this map. Cited by 172 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational, Retrospective and Prospective Study on the Use of Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy
Who cites it
172 citing papers in PubMed, 4 syntheses or guidelines pooled it, 325 citations in OpenAlex.
- Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.JCO oncology practice · 2026Pooled it
- [Chinese guideline for the diagnosis and treatment of polycythemia vera (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Guideline
- State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.Haematologica · 2019Pooled it
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Leukemia · 2018Guideline
- Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.International journal of cancer · 2026Review
- Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes.Hematology reports · 2026Review
- Article
- Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.Annals of hematology · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Article
- Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates.Cancers · 2026Review
- Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.Cancer · 2026Article
- Pre-transplant JAK-inhibition improves post-transplant outcome in myelofibrosis.Clinical and experimental medicine · 2026Article
- A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis.Blood · 2026Article
- Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology.Blood advances · 2026Article
- Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.Blood advances · 2026Article
- [External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis.European journal of haematology · 2026Article
- Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.Frontiers in oncology · 2026Review
- Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report.Journal of clinical medicine · 2025Article
112 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 19 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level <11 g/dl, to circulating blasts ⩾3%, and to CALR-unmutated genotype, 1 point to platelet count <150 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.